UBS analyst Andrew Monk downgraded Cano Health to Neutral from Buy with a price target of $1.25, down from $12. With a backdrop of slowing economic growth, higher interest rates, and greater market volatility, the analyst took a fresh look at estimates, fundamentals and valuations for value-based primary care providers with a heightened focus on cash needs and profitability. In doing so, he downgraded Cano Health.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CANO:
- Cano Health downgraded to Peer Perform from Outperform at Wolfe Research
- Citi opens ‘positive Catalyst Watch’ on Cano Health
- BofA resumes Cano Health at Underperform, sees potential more guidance cuts
- Cano Health resumed with an Underperform at BofA
- Third Point sold Cano Health stake last week, Bloomberg reports
